DT Investment Partners LLC Has $11.19 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

DT Investment Partners LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,482 shares of the company’s stock after acquiring an additional 445 shares during the quarter. Johnson & Johnson comprises about 1.2% of DT Investment Partners LLC’s investment portfolio, making the stock its 20th largest position. DT Investment Partners LLC’s holdings in Johnson & Johnson were worth $11,190,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Mascoma Wealth Management LLC lifted its stake in Johnson & Johnson by 12.0% in the third quarter. Mascoma Wealth Management LLC now owns 1,966 shares of the company’s stock valued at $306,000 after buying an additional 210 shares during the period. Key Bridge Compliance LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $1,090,000. Auour Investments LLC grew its position in shares of Johnson & Johnson by 32.2% in the 3rd quarter. Auour Investments LLC now owns 1,695 shares of the company’s stock valued at $265,000 after purchasing an additional 413 shares during the period. Summit Global Investments increased its stake in Johnson & Johnson by 11.3% during the 3rd quarter. Summit Global Investments now owns 4,858 shares of the company’s stock worth $757,000 after purchasing an additional 494 shares in the last quarter. Finally, Sunflower Bank N.A. raised its holdings in Johnson & Johnson by 2.9% during the 3rd quarter. Sunflower Bank N.A. now owns 10,215 shares of the company’s stock worth $1,591,000 after buying an additional 285 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $146.82 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm has a market capitalization of $353.80 billion, a PE ratio of 9.15, a PEG ratio of 2.45 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The business’s 50-day simple moving average is $155.47 and its 200 day simple moving average is $155.41.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.68 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 29.68%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JNJ. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada cut their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.